Dopamine transporter-dependent and -independent actions of trace amine β-phenylethylamine

Journal of Neurochemistry

Volumn 91, Issue 2, 2004, Pages 362-373

  Sotnikova, Tatyana D ^a   Budygin, Evgeny A ^b   Jones, Sara R ^b   Dykstra, Linda A ^c   Caron, Marc G ^a   Gainetdinov, Raul R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Attention deficit hyperactivity disorder; Microdialysis; Psychostimulant; Trace amines; Voltammetry

Indexed keywords

AMINE; AMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; PHENETHYLAMINE;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; HETEROZYGOSITY; HYPERACTIVITY; LOCOMOTION; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY;

ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; EXTRACELLULAR FLUID; FEMALE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; MICRODIALYSIS; MOTOR ACTIVITY; NEOSTRIATUM; NERVE TISSUE PROTEINS; PHENETHYLAMINES; STEREOTYPED BEHAVIOR; WAKEFULNESS;

ANIMALIA;

EID: 5444223715     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02721.x     Document Type: Article

References (75)

1. Amara S. G. and Sonders M. S. (1998) Neurotransmitter transportes as molecular targets for addictive drugs. Drug Alcohol Depend. 51, 87-96.
2. Bailey B. A., Philips S. R. and Boulton A. A. (1987) In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine. Neurochem. Res. 12, 173-178.
3. Baker G. B., Bomstein R. A., Rouget A. C., Ashton S. E., van Muyden J. C. and Courts R. T. (1991) Phenylethylaminergic mechanisms in attention-deficit disorder. Biol. Psychiatry 29, 15-22.
4. Baker G. B., Bornstein R. A. and Yeragani V. K. (1993) Trace amines and Tourette's syndrome. Neurochem. Res. 18, 951-956.
5. Barr A. M., Lehmann-Masten V., Paulus M., Gainetdinov R. R., Caron M. G. and Geyer M. A. (2004) The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29, 221-228.
6. Barroso N. and Rodriguez M. (1996) Action of β-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Eur. J. Pharmacol. 297, 195-203.
7. Bergman J., Yasar S. and Winger G. (2001) Psychomotor stimulant effects of β-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology 159, 21-30.
8. Borowsky B., Adham N., Jones K. A. et al. (2001) Trace amines: identifications of a family of mammalian G protein coupled receptors. Proc. Natl Acad. Sci. USA 98, 8966-8971.
9. Bosse R., Fumagalli F., Jaber M., Giros B., Gainetdinov R. R., Wetsel W. C., Missale C. and Caron M. G. (1997) Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 19, 127-138.
10. Boulton A. A. (1982) Some aspects of basic psychopharmacology: the trace amines. Prog. Neuropsychopharmacol. Biol. Psychiatry 6, 563-570.
11. Boulton A. A. (1983) Trace amines and the neurosciences: an overview, in Neurobiology of the Trace Amines (Boulton A. A., Baker G. B., Dewhurst W. G. and Sandier M., eds), pp. 13-24. Humana Press, Clifton.
12. Boulton A. A., Jurio A. V. and Paterson I. A. (1990) Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission. J. Neural Transm. Suppl. 29, 119-129.
13. Branchek T. A. and Blackburn T. P. (2003) Trace amines receptors as targets for novel therapeutics: legend, myth and fact. Curr. Opin. Pharmacol. 3, 90-97.
14. Budygin E. A., Phillips P. E., Wightman R. M. and Jones S. R. (2001) Terminal effects of ethanol on dopamine dynamics in rat nucleus accumbens: an in vitro voltammetric study. Synapse 42, 77-79.
15. Budygin E. A., John C. E., Mateo Y. and Jones S. R. (2002) Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice. J. Neurosci. 22, RC222: 1-4.
16. Budygin E. A., Brodie M., Sotnikova T. D., Mateo Y., John C. E., Cyr M., Gainetdinov R. R. and Jones S. R. (2004) Dissociation of dopamine transporter-mediated and rewarding properties of amphetamine. Proc. Natl Acad. Sci. USA 101, 7781-7786.
17. Bunzow J. R., Sonders M. S. et al. (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptors. Mol. Pharmacol. 60, 1181-1188.
18. Carboni E., Spielewoy C., Vacca C., Nosten-Bertrand M., Giros B. and Di Chiara G. (2001) Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21, RC141: 1-4.
19. Dourish C. T. (1981) Behavioral effects of acute and chronic β-phenylethylamine administration in the rat: evidence for the involvement of 5-hydroxytryptamine. Neuropharmacology 20, 1067-1072.
20. Dourish C. T. (1982) A pharmacological analysis of the hyperactivity syndrome induced by β-phenylethylamine in the mouse. Br. J. Pharmacol. 77, 129-139.
21. Dyck L. E. (1983) Release of monoamines from striatal slices by phenelzine and β-phenylethylamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 7, 797-800.
22. Filip M. and Cunningham K. A. (2003) Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. J. Pharmacol. Exp. Ther. 306, 734-743.
23. Franklin K. B. J. and Paxinos G. (1996) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
24. Gainetdinov R. R. and Caron M. G. (2003) Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 2003, 261-284.
25. Gainetdinov R. R., Fumagalli F., Jones S. R. and Caron M. G. (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325.
26. Gainetdinov R. R., Wetsel W. C., Jones S. R., Levin E. D., Jaber M. and Caron M. G. (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397-401.
27. Gainetdinov R. R., Mohn A. R., Bohn L. M. and Caron M. G. (2001) Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc. Natl. Acad. Sci. USA 98, 11047-11054.
28. Gainetdinov R. R., Sotnikova T. D. and Caron M. G. (2002) Monoamine transporter pharamacology and mutant mice. Trends Pharmacol. Sci. 23, 367-373.
29. Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
30. Greenshaw A. J. (1989) Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action. Prog. Neuropsychopharmacol. Biol. Psychiatry 13, 431-443.
31. 3H]-beta-phenylethylamine binding sites in rat brain. Eur. J. Pharmacol. 83, 147-148.
32. Holschneider D. P., Chen K., Seif I. and Shih J. C. (2001) Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res. Bull. 56, 453-462.
33. Hom A. S. and Snyder S. H. (1972) Steric requirements for catecholamine uptake by rat brain synaptosomes: studies with rigid analogs of amphetamine. J. Pharmacol. Exp. Ther. 180, 523-530.
34. Janssen P. A., Leysen J. E., Megens A. A. and Awouters F. H. (1999) Does phenylethylamine act as endogenous amphetamine in some patients? Int. J. Neuropsychopharmacol. 2, 229-240.
35. Jones S. R., Gainetdinov R. R., Jaber M., Giros B., Wightman R. M. and Caron M. G. (1998a) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA 95, 4029-4034.
36. Jones S. R., Gainetdinov R. R., Wightman R. M. and Caron M. G. (1998b) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 1979-1986.
37. Jones S. R., Gainetdinov R. R., Hu X. T., Cooper D. C., Wightman R. M., White F. J. and Caron M. G. (1999) Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat. Neurosci. 2, 649-655.
38. Kim K.-A. and Von Zastrow M. (2001) Old drugs learn new tricks: insights from mammalian trace amine receptors. Mol. Pharmacol. 60, 1165-1167.
39. Kuhr W. G., Ewings A. G., Near J. A. and Wightman R. M. (1985) Amphetamine attenuates the stimulated release of dopamine in vivo. J. Pharmacol. Exp. Ther. 232, 388-394.
40. Kusaga A., Yamashita Y., Koeda T., Hiratani M. C., Kaneko M., Yamada S. and Matsuishi T. (2002) Increased urine phenylethylamine after methylphenidate treatment in children with ADHD. Ann. Neurol. 52, 372-374.
41. Lapin I. P. (1996) Antagonism by CPP, (±)-3-(2-carboxypiperazin-4- yl)-propyl-1-phosphonic acid, of β-phenylethylamine (PEA)-induced hypermotility in mice of different strains. Pharmacol. Biochem. Behav. 55, 175-178.
42. Liang N. Y. and Rutledge C. O. (1982) Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem. Pharmacol. 31, 2479-2484.
43. Mack F. and Bonisch H. (1979) Dissociation constants and lipophicility of catecholamines and related compounds. Naunyn-Schmiedebergs Arch. Pharmacol. 310, 1-9.
44. Martin P., Waters N., Schmidt C. J., Carlsson A. and Carlsson M. L. (1998) Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm. 105, 365-396.
45. Mateo Y, Budygin. E. A., John C. E. and Jones S. R. (2004) Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc. Natl Acad. Sci. USA 101, 372-377.
46. Mcnamara F. N., Clifford J. J., Tighe O., Kinsella A., Drago J., Fuchs S., Croke D. T. and Waddington J. L. (2002) Phenotypic, ethologically based resolution of spontaneous and D2-like vs D1-like agonist-induced behavioral topography in mice with congenic D3 dopamine receptor 'knockout'. Synapse 46, 19-31.
47. Michael D., Travis E. R. and Wightman R. M. (1998) Color images for fast-scan CV measurements in biological system. Anal. Chem. 70, 586A-592A.
48. Mohn A. R., Gainetdinov R. R., Caron M. G. and Koller B. H. (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
49. Morice E., Denis C., Giros B. and Nosten-Bertrand M. (2004) Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur. J. Neurosci. 20, 120-126.
50. Nakamura M., Ishii A. and Nakahara D. (1998) Characterization of β-phenylethylamine-induced monoamine release in rat nucleus accumbens: a microdialysis study. Eur. J. Pharmacol. 349, 163-169.
51. O'Reilly R. L. and Davis B. A. (1994) Phenylethylamine and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 18, 63-75.
52. Parker E. M. and Cubeddu L. X. (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245, 199-210.
53. Paterson I. A., Jurio A. V. and Boulton A. A. (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem. 55, 1827-1837.
54. Philips S. R. (1986) In vivo release of endogenous dopamine from rat caudate nucleus by β-phenylethylamine and α, α- dideutero-β-phenylethylamine. Life Sci. 39, 2395-2400.
55. Powell S. B., Lehmann-Masten V. D., Paulus M. P., Gainetdinov R. R., Caron M. G. and Geyer M. A. (2004) MDMA 'ecstasy' alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology 173, 310-317.
56. Premont R. T., Gainetdinov R. R. and Caron M. G. (2001) Following the trace amines of elusive amines. Proc. Natl Acad. Sci. USA 98, 9474-9475.
57. Raiteri M., Del Carmine R., Bertollini A. and Levi G. (1977) Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine, and 5-hydroxytryptamine. Eur. J. Pharmacol. 41, 133-143.
58. Ralph R. J., Paulus M. P., Fumagalli F., Caron M. G. and Geyer M. A. (2001) Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 21, 305-313.
59. Rocha B. A., Fumagalli F., Gainetdinov R. R., Jones S. R., Ator R., Giros B., Miller G. W. and Caron M. G. (1998) Cocaine self-administration in dopamine transporter knockout mice. Nat. Neurosci. 1, 132-137.
60. Rocha B. A., Goulding E. H., O'Dell L. E., Mead A. N., Coufal N. G., Parsons L. H. and Tecott L. H. (2002) Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J. Neurosci. 22, 10039-10045.
61. Saavedra J. M. (1989) β-Phenylethylamine, phenylethanolamine, tyramine and octopamine, in Catecholamines II (Trendelenburg U. and Weiner N., eds), pp. 181-210. Springer-Verlag, London.
62. Sandler M., Ruthven C. R., Goodwin B. L., Reynolds G. P., Rao V. A. and Coppen A. (1980) Trace amine deficit in depressive illness: the phenylalanine connexion. Acta Psychiatr. Scand. Suppl. 280, 29-39.
63. Scanlan T. S., Suchland K. L., Hart M. E. et al. (2004) 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 10, 638-642.
64. Schmitz Y., Lee C. J., Schmauss C., Gonon F. and Sulzer D. (2001) Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21, 5916-5924.
65. Seiden L. S., Sabol K. E. and Ricaurte G. A. (1993) Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol 33, 639-677.
66. Sloviter R. S., Connor J. D. and Drust E. G. (1980) Serotoninergic properties of β-phenylethylamine in rats. Neuropharmacology 19, 1071-1074.
67. Spielewoy C., Biala G., Roubert C., Hamon M., Betancur C. and Giros B. (2001) Hypolocomotor effects of acute and daily D-amphetamine in mice lacking the dopamine transporter. Psychopharmacology 159, 2-9.
68. Stamford J. A., Kruk Z. L. and Millar J. (1986) An in vivo voltammetric comparison of the effects of three psychomotor stimulants on electrically evoked neostriatal dopamine release. Brain Res. 366, 350-353.
69. Sulzer D., Chen T. K., Lau Y. Y, Kristensen H., Rayport S. and Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108.
70. Usdin E. and Sandler M. (1976) Trace Amines and the Brain. Dekker, New York.
71. Westerink B. H. and Kikkert R. J. (1986) Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J. Nerochem. 46, 1145-1152.
72. Westerink B. H., Tuntler J., Damsma G., Rollema H. and de Vries J. B. (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn Schmiedebergs Arch. Pharmacol. 336, 502-507.
73. Wu Q., Reith M. E., Wightman R. M., Kawagoe K. T and Garris P. A. (2001) Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry. J. Neurosci. Meth. 112, 119-133.
74. 3H]amphetamine with rat brain synaptosomes. II. Active transport. J. Pharmacol. Exp. Ther. 257, 830-835.
75. 3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J. Pharmacol. Exp. Ther. 257, 820-829.